GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Generate Biomedicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.56+0.47 (+3.89%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- –
- Dividend yield
- –
Generate Biomedicines statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Generate Biomedicines | Industry median |
|---|---|---|
| Market Cap | $1.61B | $166.30M |
| Enterprise Value | $1.15B | $88.19M |
| PB Ratio | 3.53 | 2.03 |
| P/TBV Ratio | 3.53 | 2.29 |
Balance sheet
| Measure | Generate Biomedicines | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $457.40M | $61.43M |
| Net Cash (Debt) | $457.40M | $15.35M |
| Net Cash Per Share | $3.56 | $0.66 |
| Equity (Book Value) | $456.05M | $49.09M |
| Book Value Per Share | $3.55 | $1.37 |
| Tangible Book Value | $456.05M | $23.52M |
| Working Capital | $413.62M | $76.81M |
Financial position
| Measure | Generate Biomedicines | Industry median |
|---|---|---|
| Current Ratio | 8.30 | 3.34 |
| Quick Ratio | 8.08 | 2.44 |
Shares
| Measure | Generate Biomedicines | Industry median |
|---|---|---|
| Shares Outstanding | 128,352,000 | 58,127,000 |
| Shares Change (QoQ) | 0.06% | 0.54% |
| Float | 56,419,300 | 49,136,700 |
| Shares Held by Insiders | 56.0% | 11.6% |
| Shares Held by Institutions | 77.9% | 59.4% |
Scores
| Measure | Generate Biomedicines | Industry median |
|---|---|---|
| Altman Z-Score | 8.03 | -0.22 |
Calculated by StockData from Generate Biomedicines's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.